ReviewCurrent microbiology2026
A Comprehensive Review of Natural and Synthetic Flavonoids as Antibiofilm Agents Against Bacterial Biofilms.
Review in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Bacterial biofilms are a major contributor to antimicrobial resistance due to their ability to protect embedded cells from antibiotics and host immune responses. This review systematically summarizes and critically evaluates recent advances in the development of natural and synthetic flavonoids as antibiofilm agents against clinically relevant bacterial biofilms. The manuscript is organized to first outline the molecular basis of biofilm formation and resistance, followed by a detailed analysis of plant-derived flavonoids reported to inhibit biofilm formation, disrupt mature biofilms or interfere with quorum sensing pathways. The advances in synthetic flavonoid analogues including flavones, flavanones, aurones, and other functionalized derivatives are reviewed with emphasis on structure-activity relationships and antibiofilm mechanisms. Recent progress in synthetic strategies such as late-stage functionalization, C-H activation, and biocatalytic modifications is discussed in the context of improving potency, selectivity, and pharmacokinetic properties. The current limitations, challenges involved with in-vivo translation and future directions for flavonoid-based antibiofilm drug development are highlighted. This comprehensive assessment underscores the potential of flavonoids as versatile antibiofilm scaffolds while identifying critical gaps that must be addressed for clinical advancement.
Indexed as
Identifiers
42533128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.